OnCo

GRIN2A (Glutamate receptor ionotropic, NMDA 2A) is a gene that drives cell growth when it is altered. The public catalogues list it as a drug target, an oncogene driver and a fusion partner, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Colorectal cancer, Lung cancer, Skin cancer and 5 more. This dossier gathers the 0 products (0 approved), 0 trials, 0 pathways and 0 resistance routes in the corpus that involve it, with external identifiers so it can be joined to UniProt, ChEMBL, Open Targets and the rest of biology.

Biology

Component of N-methyl-D-aspartate (NMDA) receptors (NMDARs) that function as heterotetrameric, ligand-gated cation channels with high calcium permeability and voltage-dependent block by Mg(2+). NMDARs participate in synaptic plasticity for learning and memory formation by contributing to the slow phase of excitatory postsynaptic current, long-term synaptic potentiation, and learning. Channel activation requires binding of the neurotransmitter L-glutamate to the GluN2 subunit, glycine or D-serine binding to the GluN1 subunit, plus membrane depolarisation to eliminate channel inhibition by Mg(2+). NMDARs mediate simultaneously the potassium efflux and the influx of calcium and sodium. Each GluN2 subunit confers differential attributes to channel properties, including activation, deactivation and desensitisation kinetics, pH sensitivity, Ca2(+) permeability, and binding to allosteric modulators. Participates in the synaptic plasticity regulation through activation by the L-glutamate releaseed by BEST1, into the synaptic cleft, upon F2R/PAR-1 activation in astrocyte. Location: Cell projection, dendritic spine; Cell membrane; Synapse; Postsynaptic cell membrane (UniProt). Locus 16p13.2 (HGNC).

Where it is found
  • Colorectal cancer: IntOGen driver in 2 cohorts (COADREAD)
  • Lung cancer: Open Targets association 0.58 with lung cancer (MONDO_0008903)
  • Skin cancer: Open Targets association 0.57 with skin cancer (MONDO_0002898)
  • Bladder & urothelial cancer: IntOGen driver in 1 cohort (BLCA)
  • Pancreatic ductal adenocarcinoma: IntOGen driver in 1 cohort (PANCREAS)
  • Breast cancer: Open Targets association 0.57 with breast cancer (MONDO_0007254)
Class: oncogene · Gene: GRIN2A · Facts checked 2026-09-23 · Target page

External identifiers

Built from HGNC, Ensembl, UniProt and ChEMBL ids

Products by modality and phase

Browse products →

No product in the corpus is aimed at this target yet.

No trial in the corpus names this target or one of its products.

Resistance routes

Unaddressed routes →

The resistance atlas has no route that names this target.

No pathway diagram carries this target as a node.

Companion diagnostics

Assay registry →

No companion diagnostic in the registry measures this target.

Preclinical models

All models →

No model entry for this target yet; check the cancer entries on the models page.

No open questions recorded for this target yet. Suggest one.

Literature

Preprints →
Latest papers · live from Europe PMC
Open in Europe PMC

Query for this target: (TITLE:"GRIN2A" OR ABSTRACT:"GRIN2A" OR TITLE:"glutamate ionotropic receptor NMDA type subunit 2A" OR ABSTRACT:"glutamate ionotropic receptor NMDA type subunit 2A" OR TITLE:"Glutamate receptor ionotropic, NMDA 2A" OR ABSTRACT:"Glutamate receptor ionotropic, NMDA 2A" OR TITLE:"GluN2A" OR ABSTRACT:"GluN2A" OR TITLE:"NR2A" OR ABSTRACT:"NR2A" OR TITLE:"NMDAR2A" OR ABSTRACT:"NMDAR2A") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about GRIN2A, not a curated reading list.

Export

The dossier as machine-readable JSON: identifiers from HGNC, Ensembl, UniProt and ChEMBL, products with status, trials, pathways, hotspots, open questions and assays. The full entity record is in the open API at /api/v1/entities/grin2a.json. Licence CC BY-NC 4.0.